Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 41
Filtrar
1.
Epilepsia Open ; 2024 Apr 04.
Artículo en Inglés | MEDLINE | ID: mdl-38576178

RESUMEN

OBJECTIVE: Evaluate efficacy, safety, and tolerability of adjunctive brivaracetam (BRV) in adult Asian patients with focal-onset seizures (FOS). METHODS: Phase III, randomized, double-blind, placebo-controlled study (EP0083; NCT03083665) evaluating BRV 50 mg/day and 200 mg/day in patients (≥16-80 years) with FOS with/without secondary generalization (focal to bilateral tonic-clonic seizures) despite current treatment with 1 or 2 concomitant antiseizure medications. Following an 8-week baseline, patients were randomized 1:1:1 to placebo, BRV 50 mg/day, or BRV 200 mg/day, and entered a 12-week treatment period. Efficacy outcomes: percent reduction over placebo in 28-day FOS frequency (primary); 50% responder rate in FOS frequency; median percent reduction in FOS frequency from baseline; seizure freedom during treatment period (secondary). Primary safety endpoints: incidences of treatment-emergent adverse events (TEAEs); TEAEs leading to discontinuation; serious TEAEs. RESULTS: In this study, 448/449 randomized patients (mean age, 34.5 years; 53.8% female) received ≥1 dose of study medication (placebo/BRV 50 mg/BRV 200 mg/day: n = 149/151/148). Percent reduction over placebo in 28-day adjusted FOS frequency was 24.5% (p = 0.0005) and 33.4% (p < 0.0001) with BRV 50 mg/day and 200 mg/day, respectively, 50% responder rate was 19.0%, 41.1%, and 49.3% with placebo, BRV 50 mg/day, and BRV 200 mg/day, respectively (p < 0.0001 for both BRV groups vs. placebo). Median percent reduction in FOS frequency from baseline was 21.3%/38.9%/46.7% in patients on placebo/BRV 50 mg/BRV 200 mg/day, respectively. Overall, 0, 7 (4.6%), and 10 (6.8%) patients were classified as seizure-free during the treatment period on placebo, BRV 50 mg/day, and BRV 200 mg/day, respectively (p = 0.0146/p = 0.0017 for BRV 50 mg/200 mg/day vs. placebo, respectively). TEAE incidences were similar between patients on placebo (58.4%) and all patients receiving BRV (58.5%); TEAE incidences for BRV 50 mg/day and BRV 200 mg/day were 57.0% and 60.1%, respectively. Overall, 0.7% of patients on placebo and 2.0% of all patients on BRV reported serious TEAEs (incidences for BRV 50 mg/day and BRV 200 mg/day were 1.3% and 2.7%, respectively), 20.1% of patients on placebo and 33.1% of all patients on BRV reported drug-related TEAEs (incidences for BRV 50 mg/day and BRV 200 mg/day were 26.5% and 39.9%, respectively), and 4.7% of patients on placebo and 3.0% of all patients on BRV discontinued due to TEAEs (discontinuation incidences for BRV 50 mg/day and BRV 200 mg/day were 2.6% and 3.4%, respectively). SIGNIFICANCE: Adjunctive BRV was efficacious and well tolerated in adult Asian patients with FOS. Efficacy and safety profiles were consistent with BRV studies in predominantly non-Asian populations. PLAIN LANGUAGE SUMMARY: Brivaracetam is used to treat partial or focal seizures in people with epilepsy. Most studies with brivaracetam tablets have involved people from non-Asian racial backgrounds. In this study, 449 Asian adults with epilepsy took part. One third took 50 mg of brivaracetam, one third took 200 mg of brivaracetam, and one third took a placebo each day for 12 weeks. On average, those who took brivaracetam had fewer seizures than those given the placebo. Most of the side effects were mild and the number and type of side effects seen were as expected for this medication.

2.
Ci Ji Yi Xue Za Zhi ; 32(3): 291-297, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32955525

RESUMEN

OBJECTIVE: The biopsychosocial (BPS) model has been proposed to take into account the interaction of psychological and social factors in medical practice. Although some studies have explored its application in medical education, little has been evaluated about students' reflection in such courses. This study introduced a BPS model course and aimed to assess changes in students' reflective capacity resulting from this course. MATERIALS AND METHODS: Eighty-seven written reflections before and after the course were segmented, coded, and rated using the Reflection Evaluation for Learners' Enhanced Competencies Tool rubric, which contains six factors of reflective capacity, namely description of disease experience, presence, attending to emotions, description of conflict or disorienting dilemma, meaning making, and action. RESULTS: After the BPS model course, the overall reflective capacity, as well as the "Presence" and "Meaning making" scores, increased, while scores for "Attending to emotion" decreased significantly. "Description of disease experience," "Description of conflict or disorienting dilemma," and "Action" showed no significant change. CONCLUSION: Pedagogical suggestions are discussed for a BPS model course with reflective training for young medical students.

3.
Neuromodulation ; 23(3): 399-406, 2020 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-31840383

RESUMEN

OBJECTIVE: To investigate whether indicators of cortical excitability are good biomarkers of seizure controllability in temporal lobe epilepsy (TLE). MATERIALS AND METHODS: Three groups of subjects were recruited: those with poorly controlled (PC) TLE (N = 41), well-controlled (WC) TLE (N = 71), and healthy controls (N = 44). Short- and long-latency recovery curves were obtained by paired-pulse transcranial magnetic stimulation. Linear mixed effect models were used to study the effects of group, interstimulus interval (ISI), and antiepileptic drugs on long-interval intracortical inhibition (LICI) and short-interval intracortical inhibition (SICI) and intracortical facilitation (ICF). RESULTS: The mixed effect model that did not incorporate antiepileptic drugs showed that group and ISI were significant factors for LICI and SICI/ICF. LICI in the healthy control group was greater than in the two epilepsy groups, and the difference was significant at ISIs of 50, 150, and 200 msec. In contrast, SICI/ICF in the PC group was greater than in the healthy control and WC groups, and the difference was significant at an ISI of 15 msec. However, due to large variance, it was difficult to identify a cutoff value with both good sensitivity and good specificity. Incorporating the information of antiepileptic drugs to the mixed effect model did not change the overall results. CONCLUSIONS: Although LICI and SICI/ICF parameters were significantly different at the group level, they may not be suitable biomarkers for the controllability of TLE at the subject level.


Asunto(s)
Excitabilidad Cortical , Epilepsia Refractaria/fisiopatología , Epilepsia del Lóbulo Temporal/fisiopatología , Convulsiones/fisiopatología , Estimulación Magnética Transcraneal/métodos , Adulto , Anticonvulsivantes/uso terapéutico , Corteza Cerebral/fisiopatología , Excitabilidad Cortical/efectos de los fármacos , Epilepsia Refractaria/tratamiento farmacológico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Convulsiones/prevención & control , Resultado del Tratamiento
4.
Epilepsia ; 60 Suppl 1: 37-46, 2019 03.
Artículo en Inglés | MEDLINE | ID: mdl-30869165

RESUMEN

People of different ethnic or racial backgrounds may experience variations in pharmacokinetic and pharmacodynamic responses to drug therapies. Our post hoc analysis evaluated the efficacy, safety, and tolerability of perampanel in Asian and non-Asian populations with refractory focal seizures with or without focal to bilateral tonic-clonic (FBTC) seizures. This analysis pooled data from 4 randomized, placebo-controlled, phase-3 studies involving patients aged ≥12 years who have focal seizures with or without FBTC seizures. Patients were receiving 2, 4, 8, or 12 mg perampanel (or placebo) by the end of a 6-week titration period and for a further 13 weeks during the maintenance phase. Efficacy endpoints included median percent change in seizure frequency per 28 days, and 50% and seizure-freedom responder rates relative to baseline. The median percent change in seizure frequency per 28 days from baseline was significantly greater than placebo for perampanel 8 and 12 mg (-31.1% and -38.1% change, respectively; each P < 0.0001) in the Asian population, and for perampanel 4, 8, and 12 mg (-21.1% [P = 0.0001], -26.3% [P < 0.0001], and -27.7% [P = 0.0001] change, respectively) in the non-Asian population. The 50% responder rate relative to baseline was significantly greater than placebo for perampanel 8 and 12 mg (40.1% and 43.8%, respectively; each P < 0.0001) in the Asian population, and for perampanel 4, 8, and 12 mg (29.4% [P = 0.0002], 32.8% [P < 0.0001] and 34.5% [P = 0.0001]), respectively, in the non-Asian population. Seizure-freedom rate among all patients was 4.9%-11.7% for perampanel 2, 4, 8, and 12 mg. The most frequently reported treatment-emergent adverse events (TEAEs) across both populations were dizziness, somnolence, irritability, headache, and fatigue. The most common psychiatric TEAEs were aggression and irritability. Perampanel demonstrated a favorable and similar risk-benefit profile in both Asian and non-Asian populations with refractory focal seizures.


Asunto(s)
Anticonvulsivantes/uso terapéutico , Epilepsia Refractaria/tratamiento farmacológico , Piridonas/uso terapéutico , Receptores AMPA/antagonistas & inhibidores , Convulsiones/tratamiento farmacológico , Adolescente , Adulto , Anciano , Anticonvulsivantes/administración & dosificación , Pueblo Asiatico , Niño , Método Doble Ciego , Epilepsia Tónico-Clónica/tratamiento farmacológico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Nitrilos , Piridonas/administración & dosificación , Piridonas/efectos adversos , Medición de Riesgo , Resultado del Tratamiento , Adulto Joven
5.
Seizure ; 62: 84-90, 2018 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-30308428

RESUMEN

PURPOSE: The aim of this trial was to compare the efficacy and safety of two formulations of levetiracetam in people with partial epilepsy over a 12-week treatment period. METHODS: We performed a randomized, paralleled, and multicenter trial that consisted of a 4-week single-blind placebo run-in, followed by a 12-week double-blind, double-dummy treatment phase to compare the efficacy and safety of levetiracetam extended-release (LEV-ER) and immediate-release (LEV-IR) tablets as an adjunctive treatment in adult patients with uncontrolled epilepsy. RESULTS: The median partial-onset seizure (POS) frequency per week (min-max) was 0.3 (0.0, 17.4; 95% confidence interval [95% CI] 1.3, 4.8) in the LEV-ER group and 0.3 (0.0, 31.4; 95% CI - 0.1, 4.3) in the LEV-IR group. No serious adverse events occurred during the trial period. Both groups had the same responder rate (58.6%), while a higher rate of seizure freedom over the treatment period was noted in the LEV-ER group compared with the LEV-IR group (27.6% vs. 13.8%, respectively). The European Quality of Life-5 Dimensions scores significantly increased in the LEV-ER-treated group, in contrast to the scores in the LEV-IR group, which decreased (7.2 vs. - 1.5, p = 0.03). CONCLUSION: These results suggest that LEV-ER is equivalent to LEV-IR in reducing the frequency of POS and has a similar tolerability as LEV-IR as an add-on therapy. In addition, LEV-ER treatment improved the health-related quality of life of people with uncontrolled partial epilepsy.


Asunto(s)
Anticonvulsivantes/administración & dosificación , Epilepsias Parciales/tratamiento farmacológico , Levetiracetam/administración & dosificación , Resultado del Tratamiento , Adolescente , Adulto , Método Doble Ciego , Sistemas de Liberación de Medicamentos , Epilepsias Parciales/psicología , Femenino , Humanos , Masculino , Calidad de Vida/psicología , Factores de Tiempo , Adulto Joven
6.
Neurotox Res ; 34(1): 1-15, 2018 07.
Artículo en Inglés | MEDLINE | ID: mdl-29188487

RESUMEN

How sodium metabisulfite (SMB; Na2S2O5), a popular food preservative and antioxidant, interacts with excitable membrane and induces excitotoxicity is incompletely understood. In this study, the patch-clamp technique was used to investigate and record the electrophysiological effect of SMB on electrically excitable HL-1 cardiomyocytes and NSC-34 neurons, as well as its relationship to pilocarpine-induced seizures and neuronal excitotoxicity in rats. We used Western blotting, to analyze sodium channel expression on hippocampi after chronic SMB treatment. It was found that voltage-gated Na+ current (I Na) was stimulated, and current inactivation and deactivation were slowed in SMB-treated (30 µM) HL-1 cardiomyocytes. SMB-induced increases of I Na were attenuated in cells treated with ranolazine (10 µM) or eugenol (30 µM). The current-voltage relationship of I Na shifted to slightly more negative potentials in SMB-treated cells, the peak I Na with an EC50 value of 18 µM increased, and the steady-state inactivation curve of I Na shifted to a more positive potential. However, the tail component of the rapidly activating delayed-rectifier K+ current (I Kr) was dose-dependently inhibited. Cell-attached voltage-clamp recordings in SMB-treated cells showed that the frequency of action currents and prolonged action potential were higher. In SMB-treated NSC-34 neurons, the peak I Na was higher; however, neither the time to peak nor the inactivation time constant (I Na) changed. Pilocarpine-induced seizures were exacerbated, and acute neuronal damage and chronic mossy fiber sprouting increased in SMB-treated rats. Western blotting showed higher expression of the sodium channel in cells after chronic SMB treatment. We conclude that SMB contributes to the sodium channel-activating mechanism through which it alters cellular excitability and excitotoxicity in wide-spectrum excitable cells.


Asunto(s)
Broncoconstrictores/farmacología , Canales Iónicos/efectos de los fármacos , Potenciales de la Membrana/efectos de los fármacos , Convulsiones/tratamiento farmacológico , Sulfitos/farmacología , Alopecia/inducido químicamente , Animales , Biofisica , Peso Corporal/efectos de los fármacos , Broncoconstrictores/uso terapéutico , Línea Celular Transformada , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Estimulación Eléctrica , Expresión Génica/efectos de los fármacos , Canales Iónicos/fisiología , Masculino , Ratones , Agonistas Muscarínicos/toxicidad , Miocitos Cardíacos/efectos de los fármacos , Miocitos Cardíacos/fisiología , Canal de Sodio Activado por Voltaje NAV1.1/genética , Canal de Sodio Activado por Voltaje NAV1.1/metabolismo , Neuronas/efectos de los fármacos , Neuronas/fisiología , Pilocarpina/toxicidad , Ratas , Ratas Sprague-Dawley , Convulsiones/inducido químicamente , Convulsiones/patología , Piel/efectos de los fármacos , Piel/patología , Sulfitos/uso terapéutico
8.
Nurse Educ Today ; 35(12): 1262-7, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25979802

RESUMEN

BACKGROUND: Evidence-based practice (EBP) has been emphasized as the core competency of undergraduate nursing students and must be cultivated before graduation. However, there is limited information of EBP education for undergraduate nursing students in Taiwan. OBJECTIVES: The purpose of this study was to investigate the current state of EBP education for undergraduate nursing students in Taiwan. DESIGN: A self-developed questionnaire, validated by experienced educators, was designed to explore curriculum design, teaching resources, qualification of teachers, and barriers regarding EBP education. PARTICIPANTS: A total of 21 nursing schools and colleges participated. The chair of each recommended a faculty member involved in teaching EBP as the school's representative to fill out the questionnaire. RESULTS: Among the 21 nursing schools and colleges, 18 (85.7%) had implemented EBP education in the curriculum. Among these schools, 22.2% conducted an independent EBP course, 50% incorporated EBP concepts into other courses, and the remainder offered both kinds of EBP courses. Multiple strategies were incorporated to teach the EBP. Less than 35% of the schools had designed or adopted standardized teaching materials and evaluated students' learning outcomes. Although 55.6% of the schools reimbursed faculty for participation in EBP training, 39% of their faculty members who taught EBP did not receive any EBP training. Shortage of qualified faculty and limited opportunity to involve students in evidence-based applications were reported as major obstacles to teaching EBP. CONCLUSIONS: EBP education has already gained the attention of nursing schools in Taiwan. However, lack of comprehensive EBP training among teachers and the difficulty of teaching clinical application of EBP require special consideration. In order to promote EBP education in undergraduate nursing curriculums, we suggest that nursing schools reinforce and support faculty to participate in formal EBP training. Also needed is a systematic curriculum design with multiple teaching strategies and links with clinical practicum.


Asunto(s)
Bachillerato en Enfermería/normas , Docentes de Enfermería/normas , Estudiantes de Enfermería , Curriculum/normas , Enfermería Basada en la Evidencia , Humanos , Encuestas y Cuestionarios , Taiwán
9.
Sensors (Basel) ; 13(9): 12536-47, 2013 Sep 17.
Artículo en Inglés | MEDLINE | ID: mdl-24048343

RESUMEN

Accurate automatic spike detection is highly beneficial to clinical assessment of epileptic electroencephalogram (EEG) data. In this paper, a new two-stage approach is proposed for epileptic spike detection. First, the k-point nonlinear energy operator (k-NEO) is adopted to detect all possible spike candidates, then a newly proposed spike model with slow wave features is applied to these candidates for spike classification. Experimental results show that the proposed system, using the AdaBoost classifier, outperforms the conventional method in both two- and three-class EEG pattern classification problems. The proposed system not only achieves better accuracy for spike detection, but also provides new ability to differentiate between spikes and spikes with slow waves. Though spikes with slow waves occur frequently in epileptic EEGs, they are not used in conventional spike detection. Identifying spikes with slow waves allows the proposed system to have better capability for assisting clinical neurologists in routine EEG examinations and epileptic diagnosis.


Asunto(s)
Potenciales de Acción , Encéfalo/fisiopatología , Diagnóstico por Computador/métodos , Electroencefalografía/métodos , Epilepsia/diagnóstico , Epilepsia/fisiopatología , Modelos Neurológicos , Algoritmos , Simulación por Computador , Humanos , Reconocimiento de Normas Patrones Automatizadas/métodos , Reproducibilidad de los Resultados , Sensibilidad y Especificidad
10.
PLoS One ; 8(6): e65154, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23785408

RESUMEN

Diabetes can exacerbate seizures and worsen seizure-related brain damage. In the present study, we aimed to determine whether the standard antiepileptic drug pregabalin (PGB) protects against pilocarpine-induced seizures and excitotoxicity in diabetes. Adult male Sprague-Dawley rats were divided into either a streptozotocin (STZ)-induced diabetes group or a normal saline (NS) group. Both groups were further divided into subgroups that were treated intravenously with either PGB (15 mg/kg) or a vehicle; all groups were treated with subcutaneous pilocarpine (60 mg/kg) to induce seizures. To evaluate spontaneous recurrent seizures (SRS), PGB-pretreated rats were fed rat chow containing oral PGB (450 mg) for 28 consecutive days; vehicle-pretreated rats were fed regular chow. SRS frequency was monitored for 2 weeks from post-status epilepticus day 15. We evaluated both acute neuronal loss and chronic mossy fiber sprouting in the CA3 area. In addition, we performed patch clamp recordings to study evoked excitatory postsynaptic currents (eEPSCs) in hippocampal CA1 neurons for both vehicle-treated rats with SRS. Finally, we used an RNA interference knockdown method for Kir6.2 in a hippocampal cell line to evaluate PGB's effects in the presence of high-dose ATP. We found that compared to vehicle-treated rats, PGB-treated rats showed less severe acute seizure activity, reduced acute neuronal loss, and chronic mossy fiber sprouting. In the vehicle-treated STZ rats, eEPSC amplitude was significantly lower after PGB administration, but glibenclamide reversed this effect. The RNA interference study confirmed that PGB could counteract the ATP-sensitive potassium channel (KATP)-closing effect of high-dose ATP. By opening KATP, PGB protects against neuronal excitotoxicity, and is therefore a potential antiepileptogenic in diabetes. These findings might help develop a clinical algorithm for treating patients with epilepsy and comorbid metabolic disorders.


Asunto(s)
Anticonvulsivantes/farmacología , Neuropatías Diabéticas/metabolismo , Neuropatías Diabéticas/patología , Convulsiones/metabolismo , Convulsiones/patología , Ácido gamma-Aminobutírico/análogos & derivados , Adenosina Trifosfato/metabolismo , Animales , Anticonvulsivantes/administración & dosificación , Glucemia , Línea Celular , Neuropatías Diabéticas/inducido químicamente , Neuropatías Diabéticas/tratamiento farmacológico , Neuropatías Diabéticas/mortalidad , Modelos Animales de Enfermedad , Potenciales Postsinápticos Excitadores/efectos de los fármacos , Gliburida/administración & dosificación , Gliburida/farmacología , Hipocampo/efectos de los fármacos , Hipocampo/patología , Canales KATP/metabolismo , Masculino , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Pilocarpina/efectos adversos , Canales de Potasio de Rectificación Interna/genética , Canales de Potasio de Rectificación Interna/metabolismo , Pregabalina , Ratas , Convulsiones/inducido químicamente , Convulsiones/tratamiento farmacológico , Convulsiones/mortalidad , Estreptozocina/efectos adversos , Ácido gamma-Aminobutírico/administración & dosificación , Ácido gamma-Aminobutírico/farmacología
11.
J Clin Neurosci ; 20(5): 686-91, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-23517673

RESUMEN

Mu rhythm can be suppressed by movements, the so called event-related desynchronization (ERD). Levetiracetam (LEV) is a newer type of antiepileptic drug. A previous study reported that LEV might enhance mu rhythm and caused mu status in one subject. The main purpose of this study was to investigate the effects of LEV on EEG frequency contents and ERD. Seventeen patients with epileptic foci outside the Rolandic area were recruited. The following studies were performed before and after chronically taking LEV. An electroencephalogram (EEG) with 10 minutes of resting state and 5 minutes covering 10 right thumb movements were recorded. Reaction time was evaluated with a simple visual reaction time test. EEG data were analyzed by S-transformation and relative band powers were calculated. The results showed that the relative powers of theta, alpha and beta band in frontal (F3 and F4) and occipital (O1 and O2) leads and mu band in the centro-parietal (C3, C4, P3 and P4) leads were not changed by chronically taking LEV. No mu status was observed in any subject. However, the mean group ERD was enhanced at C3, Cz and P4 leads. Reaction time was similar before and after taking LEV. In conclusion, chronically taking LEV did not change the frequency contents of EEG and did not cause drowsiness, but enhanced ERD. The results suggest that chronically taking medication, such as LEV, is a plausible method to broaden the applicability of ERD-based brain-computer interfaces.


Asunto(s)
Anticonvulsivantes/farmacología , Ondas Encefálicas/efectos de los fármacos , Electroencefalografía/efectos de los fármacos , Epilepsias Parciales/fisiopatología , Piracetam/análogos & derivados , Adulto , Ondas Encefálicas/fisiología , Electroencefalografía/instrumentación , Electroencefalografía/métodos , Epilepsias Parciales/tratamiento farmacológico , Femenino , Humanos , Levetiracetam , Masculino , Persona de Mediana Edad , Pruebas Neuropsicológicas , Piracetam/farmacología , Tiempo de Reacción/efectos de los fármacos , Tiempo de Reacción/fisiología , Resultado del Tratamiento , Percepción Visual/efectos de los fármacos , Percepción Visual/fisiología , Adulto Joven
13.
Seizure ; 21(4): 254-9, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-22321335

RESUMEN

OBJECTIVE: Previous studies suggested a higher risk of all-cause mortality in patients with epilepsy than in the general population. However, information on the age- and sex-specific risk of mortality, as well as on the cause-specific risk of mortality has been sparse. This study aims to determine sex-, age-, and cause-specific risk of mortality among patients with epilepsy from southern Taiwan. METHODS: A total of 2180 patients treated in a tertiary hospital in southern Taiwan between 1989 and 2008 were compared to the general population of Taiwan for age-, sex- and cause-specific mortalities. The age-, sex-, and calendar year-standardized mortality ratios (SMRs) were calculated to estimate the relative risks of mortality associated with the epilepsy. RESULTS: There are 266 (12.2%) deaths noted in the study period. The patients with epilepsy experienced a significantly increased SMR of all-cause mortality (SMR, 2.5; 95% confidence interval (CI), 2.2-2.8). The most significantly elevated age-specific SMR was 51.8 (95% CI, 6.2-187.2) and 8.6 (95% CI, 4.4-14.9) for male patients aged 0-9 years and female patients aged 20-29 years, respectively. Additionally, the most increased cause-specific SMR was noted for brain tumor (SMR, 21.4; 95% CI, 9.23-23.1), followed by accidental drowning (SMR, 8.8; 95% CI, 3.5-9.6) and falls (SMR, 5.7; 95% CI, 2.2-6.1). CONCLUSION: Younger epilepsy should be the object of aggressive treatments. Advancement in treating brain tumors and prevention of accidental injuries may help improve the survival of patients with epilepsy.


Asunto(s)
Epilepsia/mortalidad , Adolescente , Adulto , Distribución por Edad , Anciano , Anciano de 80 o más Años , Causas de Muerte , Niño , Preescolar , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Factores de Riesgo , Taiwán/epidemiología , Adulto Joven
14.
Psychopharmacology (Berl) ; 221(4): 575-87, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22160139

RESUMEN

RATIONALE: Eugenol (EUG, 4-allyl-2-methoxyphenol), the main component of essential oil extracted from cloves, has various uses in medicine because of its potential to modulate neuronal excitability. However, its effects on the ionic mechanisms remains incompletely understood. OBJECTIVES: We aimed to investigate EUG's effects on neuronal ionic currents and excitability, especially on voltage-gated ion currents, and to verify the effects on a hyperexcitability-temporal lobe seizure model. METHODS: With the aid of patch-clamp technology, we first investigated the effects of EUG on ionic currents in NG108-15 neuronal cells differentiated with cyclic AMP. We then used modified Pinsky-Rinzel simulation modeling to evaluate its effects on spontaneous action potentials (APs). Finally, we investigated its effects on pilocarpine-induced seizures in rats. RESULTS: EUG depressed the transient and late components of I(Na) in the neurons. It not only increased the degree of I(Na) inactivation, but specifically suppressed the non-inactivating I(Na) (I(Na(NI))). Its inhibition of I (Na(NI)) was reversed by tefluthrin. In addition, EUG diminished L-type Ca(2+) current and delayed rectifier K(+) current only at higher concentrations. EUG's effects on APs frequency reduction was verified by the simulation modeling. In pilocarpine-induced seizures, the EUG-treated rats showed no shorter seizure latency but a lower seizure severity and mortality than the control rats. The EUG's effect on seizure severity was occluded by the I(Na(NI)) antagonist riluzole. CONCLUSION: The synergistic blocking effects of I (Na) and I(Na(NI)) contributes to the main mechanism through which EUG affects the firing of neuronal APs and modulate neuronal hyperexcitability such as pilocarpine-induced temporal lobe seizures.


Asunto(s)
Eugenol/farmacología , Neuronas/efectos de los fármacos , Convulsiones/tratamiento farmacológico , Canales de Sodio/efectos de los fármacos , Potenciales de Acción/efectos de los fármacos , Animales , Canales de Calcio Tipo L/efectos de los fármacos , Canales de Calcio Tipo L/metabolismo , Línea Celular Tumoral , Canales de Potasio de Tipo Rectificador Tardío/efectos de los fármacos , Canales de Potasio de Tipo Rectificador Tardío/metabolismo , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Eugenol/administración & dosificación , Glioma/metabolismo , Masculino , Ratones , Neuroblastoma/metabolismo , Neuronas/metabolismo , Técnicas de Placa-Clamp , Pilocarpina , Ratas , Ratas Sprague-Dawley , Riluzol/farmacología , Convulsiones/fisiopatología , Índice de Severidad de la Enfermedad , Canales de Sodio/metabolismo
15.
Neurol Sci ; 33(2): 331-3, 2012 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-21744107

RESUMEN

Topiramate (TPM) is a newer antiepileptic drug with high efficacy in treating various neurological disorders, especially epilepsy and migraine. The adverse effects of TPM therapy are mainly central nervous system-related somnolence and dizziness. There are rare reports about the role of TPM on sexual effects, but with inconsistent results. In this report, we describe a 31-year-old man who developed erectile dysfunction after several months of TPM use. Complete urological and sexual psychiatric evaluations were done. There was lack of an identifiable organic basis and psychiatric pathology in this patient. The erectile dysfunction improved only after the termination of TPM, documenting the temporal relationship. We reviewed and discussed the clinical aspect of TPM use in erectile dysfunction. This case and the rare cases of erectile dysfunction in TPM use reported in the literature show that TPM is worth to be paid attention to whenever it is prescribed in a wide range of neurological disorders.


Asunto(s)
Anticonvulsivantes/efectos adversos , Disfunción Eréctil/inducido químicamente , Fructosa/análogos & derivados , Adulto , Epilepsia del Lóbulo Temporal/tratamiento farmacológico , Fructosa/efectos adversos , Humanos , Masculino , Topiramato
16.
Acta Neurol Taiwan ; 20(3): 213-27, 2011 Sep.
Artículo en Chino | MEDLINE | ID: mdl-22009127

RESUMEN

The Treatment Guideline Subcommittee of the Taiwan Headache Society evaluated both the acute and the preventive treatments for cluster headache now being used in Taiwan, based on the principles of evidence- based medicine. We assessed the quality of clinical trials and levels of evidence, and referred to other treatment guidelines proposed by other countries. Throughout several panel discussions, we merged opinions from the subcommittee members and proposed a consensus on the major roles, recommended levels, clinical efficacy, adverse events and cautions of clinical practice regarding acute and preventive treatments of cluster headache. The majority of Taiwanese patients have episodic cluster headaches, because chronic clusters are very rare. Cluster headache is characterized by severe and excruciating pain which develops within a short time and is associated with ipsilateral autonomic symptoms. Therefore, emergency treatment for a cluster headache attack is extremely important. Within the group of acute medications currently available in Taiwan, the subcommittee determined that high-flow oxygen inhalation has the best evidence of effectiveness, followed by intranasal triptans. Both are recommended as first-line medical treatments for acute attacks. Oral triptans were determined to be second-line medications. For transitional prophylaxis, oral corticosteroids are recommended as the first-line medication, and ergotamine as the second-line choice. As for maintenance prophylaxis, verapamil has the best evidence and is recommended as the first-line medication. Lithium, melatonin, valproic acid, topiramate and gabapentin are suggested as the second-line preventive medications. Surgical interventions, including occipital nerve stimulation, deep brain stimulation, radiofrequency block of the sphenopalatine ganglion, percutaneous radiofrequency rhizotomy and trigeminal nerve section, are invasive and their long-term efficacy and adverse events are still not clear in Taiwanese patients; therefore, they are not recommended currently by the subcommittee. The transitional and maintenance prophylactic medications can be used together to attain treatment efficacy. Once the maintenance prophylaxis achieves efficacy, the transitional prophylactic medications can be tapered gradually. We suggest the corticosteroids be used within two weeks, if possible. The duration of maintenance treatment depends on the individual patient's clinical condition, and the medications can be tapered off when the cluster period is over.


Asunto(s)
Cefalalgia Histamínica/tratamiento farmacológico , Enfermedad Aguda , Cefalalgia Histamínica/prevención & control , Humanos , Guías de Práctica Clínica como Asunto
17.
Epilepsy Behav ; 21(1): 100-2, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-21482194

RESUMEN

Hyperventilation is a traditional seizure-provoking procedure used mainly in idiopathic generalized epilepsy and with a relatively limited role in partial epilepsy. Ictal fear is a rare seizure semiology seen in temporal lobe epilepsy. It has been suggested that the amygdala and anterior hippocampus are involved in generating ictal fear. We describe a rare patient with nonlesional temporal epilepsy who, while hyperventilating during an electroencephalography recording, developed complex partial seizures presenting as ictal fear. The particular sensitivity of the anterior hippocampus (probably the amygdala) to hypocapnia might be an important factor contributing to seizures. To avoid misdiagnosing this unusual condition as a pseudo-seizure, a detailed history and seizure semiology, as well as a concurrent electroencephalography recording, are mandatory.


Asunto(s)
Epilepsia del Lóbulo Temporal/psicología , Miedo , Adulto , Electroencefalografía , Humanos , Masculino
18.
N Engl J Med ; 364(12): 1126-33, 2011 Mar 24.
Artículo en Inglés | MEDLINE | ID: mdl-21428768

RESUMEN

BACKGROUND: Carbamazepine, an anticonvulsant and a mood-stabilizing drug, is the main cause of the Stevens-Johnson syndrome (SJS) and its related disease, toxic epidermal necrolysis (TEN), in Southeast Asian countries. Carbamazepine-induced SJS-TEN is strongly associated with the HLA-B*1502 allele. We sought to prevent carbamazepine-induced SJS-TEN by using HLA-B*1502 screening to prospectively identify subjects at genetic risk for the condition. METHODS: From 23 hospitals in Taiwan, we recruited 4877 candidate subjects who had not taken carbamazepine. We genotyped DNA purified from the subjects' peripheral blood to determine whether they carried the HLA-B*1502 allele. Those testing positive for HLA-B*1502 (7.7% of the total) were advised not to take carbamazepine and were given an alternative medication or advised to continue taking their prestudy medication; those testing negative (92.3%) were advised to take carbamazepine. We interviewed the subjects by telephone once a week for 2 months to monitor them for symptoms. We used the estimated historical incidence of SJS-TEN as a control. RESULTS: Mild, transient rash developed in 4.3% of subjects; more widespread rash developed in 0.1% of subjects, who were hospitalized. SJS-TEN did not develop in any of the HLA-B*1502-negative subjects receiving carbamazepine. In contrast, the estimated historical incidence of carbamazepine-induced SJS-TEN (0.23%) would translate into approximately 10 cases among study subjects (P<0.001). CONCLUSIONS: The identification of subjects carrying the HLA-B*1502 allele and the avoidance of carbamazepine therapy in these subjects was strongly associated with a decrease in the incidence of carbamazepine-induced SJS-TEN. (Funded by the National Science Council of Taiwan and the Taiwan Drug Relief Foundation.).


Asunto(s)
Anticonvulsivantes/efectos adversos , Carbamazepina/efectos adversos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/genética , Pruebas Genéticas , Antígenos HLA-B/genética , Síndrome de Stevens-Johnson/inducido químicamente , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Anticonvulsivantes/uso terapéutico , Pueblo Asiatico/genética , Carbamazepina/uso terapéutico , Niño , Preescolar , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/prevención & control , Femenino , Genotipo , Antígeno HLA-B15 , Humanos , Incidencia , Lactante , Masculino , Persona de Mediana Edad , Farmacogenética , Síndrome de Stevens-Johnson/epidemiología , Síndrome de Stevens-Johnson/genética , Síndrome de Stevens-Johnson/prevención & control , Taiwán , Adulto Joven
19.
Seizure ; 20(3): 240-3, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-21185206

RESUMEN

BACKGROUND: Age-period-cohort (APC) analysis could provide useful insight into the interpretation of time trends for disease rates. This study aimed to determine whether the patterns of age, period and cohort effects on epilepsy mortality in Taiwan were similar to those in the US and in England and Wales. METHODS: We employed a three-phase APC analysis method developed by Keyes and Li,(7) which conceptualizes the cohort effect as a partial interaction between age and period. The effects of age, period, and cohort were indicated by the relative risk (RR) of mortality rates. RESULTS: We found an increase in mortality rates in the elderly from 1981-85 to 2001-05 and no decline in mortality rates for children, adolescents and adults from 1991-95 to 2001-05. According to APC analysis, the RRs increased sharply during adolescence, and leveled off in adulthood, and then increased steeply in the elderly. The RR of period effects decreased from period 1971-1975 to period 1991-1995 and then increased. With the exception of cohort 1911-1915, no significant cohort effects were found. CONCLUSION: Despite the limitations of official published mortality data, we still found prominent age effects according to APC analysis, which were similar to the results of a previous study. However, the patterns of period and cohort effects in relation to epilepsy mortality in Taiwan differed from those in England and Wales and in the US.


Asunto(s)
Epilepsia/epidemiología , Epilepsia/mortalidad , Adolescente , Adulto , Factores de Edad , Anciano , Niño , Preescolar , Efecto de Cohortes , Estudios de Cohortes , Femenino , Humanos , Lactante , Masculino , Persona de Mediana Edad , Morbilidad , Estudios Retrospectivos , Taiwán/epidemiología , Adulto Joven
20.
Neurol Sci ; 32(2): 297-9, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20640465

RESUMEN

Somatosensory rub reflex epilepsy, evoked by prolonged or repetitive cutaneous contact of a circumscribed body area, is an unusual form of reflex epilepsy. The peculiar complaints and the negative interictal electroencephalographic (EEG) recordings make it difficult to identify the epileptic origin. Here we report an unusual case whose seizures would be evoked by a touch or rub on a unilateral arm and shoulder, with a contralateral temporal lobe origin, demonstrated in immediate postictal single-photon emission computed tomography (SPECT).


Asunto(s)
Epilepsia Refleja/diagnóstico por imagen , Lóbulo Temporal/diagnóstico por imagen , Tacto , Adulto , Anticonvulsivantes/uso terapéutico , Epilepsia Refleja/tratamiento farmacológico , Humanos , Masculino , Tomografía Computarizada de Emisión de Fotón Único
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...